GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Notes Receivable

ROQAF (Roquefort Therapeutics) Notes Receivable : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Notes Receivable?

Roquefort Therapeutics's Notes Receivable for the quarter that ended in Jun. 2024 was $0.00 Mil.


Roquefort Therapeutics Notes Receivable Historical Data

The historical data trend for Roquefort Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Notes Receivable Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial - - - - -

Roquefort Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Roquefort Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines